Recent Updates
Recently added Catalysts

Cerenome, Inc.

CNSYFDA catalysts, PDUFA dates & pipeline intelligence
$0.71
▲ +0.08 · +12.14%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CNSY financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
548.83 K
Value Traded
376.28 K
Short % Float
11.27%
Days to Cover
14.9
-8.27%Week
-57.93%1 Month
-76.44%3 Month

Cash Data

Unlock CNSY cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.91 M
EPS (TTM)
-3.10
P/E Ratio
-
Ent. Value
2.04 M
Total Shares
9.78 M
Float Shares
7.49 M
Insiders
1.30%
Institutions
15.92%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 interim results
REYOBIQ
Leptomeningeal metastases
Phase 2RadiopharmaceuticalsNeurology
Unlock every CNSY catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CNSY Catalyst Timeline

Dated clinical, regulatory and corporate events for Cerenome, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Cerenome, Inc.

69Total events
17Upcoming
4Tier-1 (high impact)
2025 to 2027Coverage

Upcoming catalysts 2

T2Dose Finding Update
Subscribe to view catalyst details
REYOBIQ
T2Timing Guidance
Subscribe to view catalyst details
CNSide

Event history 34

●R&D DayPresentation
Q3 2026 earnings conference call and webcast
▲Interim Efficacy DataREYOBIQClinical Data
Interim ReSPECT-LM data show no DLTs, consistent repeat-dose dosimetry, no LM progression at 3 and 6 months
leptomeningeal metastasessource ↗
▲Poster PresentationREYOBIQPresentation
Interim ReSPECT-LM repeat-dose data presented as poster at SNO 31st Annual Meeting
leptomeningeal metastasessource ↗
◆Oral PresentationREYOBIQPresentation
REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO
leptomeningeal metastasessource ↗
●Quarterly UpdateCorporate
Cerenome reports third quarter 2026 financial results and business highlights
●Management ChangeCorporate
Ron Andrews appointed Chief Business Officer
▲Reimbursement / PricingCNSidePost-Market
Aetna in-network agreement effective November 1 covering tumor cell enumeration and molecular profiling
leptomeningeal metastasessource ↗
▲Oral PresentationREYOBIQPresentation
Interim Phase 1 ReSPECT-LM multi-dose findings presented at Society of Neuro Oncology Annual meeting
leptomeningeal metastasessource ↗
▲Enrollment CompleteREYOBIQTrial
Cerenome completes enrollment in Phase 2 ReSPECT-GBM trial of REYOBIQ in recurrent GBM
recurrent glioblastomasource ↗
●Poster PresentationREYOBIQPresentation
Poster '186Rhenium-Nanoliposome (186RNL) Remodels the Tumor Microenvironment in Preclinical Ovarian Cancer Models' presented
epithelial ovarian cancersource ↗
Unlock the full CNSY catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CNSY actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-13REYOBIQ (rhenium Re186 obisbemeda) Phase 1 interim results Phase 1
Unlock all CNSY historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 81%
Micro Cap
(rank 587 of 725)
Percentile Rank
Showing 3 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
186RNL RadiopharmaceuticalsNCT01906385GliomaPhase 1/2 ACTIVE NOT_RECRUITING 95Apr 1, 2027
186RNL RadiopharmaceuticalsNCT07061626EpendymomaPhase 1 RECRUITING 56Mar 1, 2028
186RNL RadiopharmaceuticalsNCT05034497Leptomeningeal MetastasisPhase 1/2 COMPLETED 61Oct 19, 2026
Unlock the CNSY pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CNSY program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
REYOBIQ™ leptomeningeal metastases2026-11-16dose limiting toxicities: none; LM progression 3 months: 0/5; LM progression 6 months: 0/5; LM progression 9 months: 1/4; total administered activity: 79.2 mCi; doses administered: three 26.4 mCi dosesRead MoreCerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual MeetingRead More
Scroll for more · summaries link to the source press release
Unlock every CNSY trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CNSY insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Guse KyleDirectorOption 921 1,843 held$0.00 10/01/2026
Unlock the full CNSY insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in CNSY for Q3 2026.
Unlock every fund holding CNSY
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CNSY
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CNSY ownership
Insider and institutional ownership, quarter by quarter.

CNSY Short Interest

Shares sold short, counted twice a month.

11.27%
Short % of Float
of tradable shares sold short
844.0K
Shares Sold Short
+7.9% vs prior count
14.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
56.8K
Avg Daily Volume
the average used for days to cover
Unlock CNSY short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CNSY option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CNSY option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CNSY options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CNSY ranks across every disease it competes in

Competitive Position is a premium feature
See how CNSY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CNSY News

-CNSY
Nov 16, 2026
CNSYPhases
▼ -24.8%on this news

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

Cerenome presented interim data from its ReSPECT-LM study at the SNO Annual Meeting. The study evaluates repeated dosing of REYOBIQ in leptomeningeal metastases. Notably, no dose-limiting toxicities were observed, and LM progression was not documented in most patients at three and six months. The findings support the feasibility of fractionated dosing.

Read more →
-CNSY
Nov 13, 2026
CNSYGeneral
▼ -24.8%on this newsshared move

Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

Cerenome, Inc. reported its Q3 2026 financial results, highlighting the first revenue from its CNSide diagnostic platform and expansion of payer agreements. The company completed enrollment in its Phase 2 trial for recurrent glioblastoma and presented positive interim data for REYOBIQ. Despite a net loss increase, Cerenome is advancing its commercial and clinical programs.

Read more →
-CNSY
Nov 12, 2026
CNSYConferences/Events

Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16

Cerenome, Inc. will host a conference call on November 16, 2026, to review REYOBIQ ReSPECT-LM clinical data presented at the SNO conference. The call will also include a commercial update on CNSide and the company's third quarter financial results. This event highlights Cerenome's focus on CNS oncology advancements.

Read more →
-CNSY
Nov 10, 2026
CNSYGeneral
▲ +19%on this news· ran to +67% by day 3shared move

Cerenome Appoints Director Ron Andrews as Chief Business Officer

Cerenome, Inc. appointed Ron Andrews as Chief Business Officer to enhance its business development and commercial strategy. Andrews, who has over 35 years of experience in diagnostics, will focus on expanding the CNSide Diagnostics platform and forming strategic partnerships. His leadership is expected to strengthen Cerenome's position in CNS oncology.

Read more →
-CNSY
Nov 4, 2026
CNSYGeneral
▼ -31.4%on this news· ran to -56% by day 3

Cerenome Secures National In-Network Agreement with Aetna for CNSide®

Cerenome signed a national in-network agreement with Aetna for CNSide tests. The deal covers tumor cell enumeration and molecular profiling for central nervous system cancers. This addition brings 26 million members to Cerenome's payer network. Total covered lives now reach approximately 190 million across the US.

Read more →
-CNSY
Oct 29, 2026
CNSYPhases

Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma

Cerenome has completed enrollment in the Phase 2 ReSPECT-GBM trial for REYOBIQ in recurrent glioblastoma. The trial enrolled 32 patients, with topline data expected in mid-2027. Interim results showed a 63% improvement in median overall survival compared to standard care. The company plans to discuss findings with the FDA after data analysis.

Read more →
-CNSY
Oct 27, 2026
CNSYPhases
▲ +5.7%on this newsshared move

Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases

Cerenome announced it will present interim data from the ReSPECT-LMM trial at the SNO Annual Meeting. The study evaluates REYOBIQ in patients with leptomeningeal metastases, a condition with no approved treatments. The company aims to progress to a Phase 2 study in 2027, potentially leading to accelerated approval.

Read more →
-CNSY
Oct 21, 2026
CNSYPhases

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™

Cerenome announced new preclinical data for REYOBIQ, revealing its dual mechanism of action against cancer. The findings show that REYOBIQ, combined with anti-PD-1, enhances antitumor activity in ovarian cancer models. This combination improved median survival to 65 days and activated the immune response, suggesting potential for broader applications in oncology.

Read more →
-CNSY
Oct 8, 2026
CNSYGeneral
▲ +9.5%on this news

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Cerenome's subsidiary, CNSide Diagnostics, has secured an in-network agreement with Florida Blue, enhancing reimbursement for its CSF Tumor Cell Enumeration and Molecular Profile tests. This agreement adds approximately 6 million covered lives, bringing the total to 164 million. The move signifies a strategic expansion of CNSide's diagnostic capabilities for CNS oncology.

Read more →
-CNSY
Oct 6, 2026
CNSYGeneral

Cerenome Launches CNSide® CSF Molecular Profile Tests

Cerenome, Inc. has announced the launch of two new cerebrospinal fluid-based molecular profiling tests, CNSide® CSF Molecular Profile for solid tumors and hematologic malignancies. These tests will provide extensive DNA and RNA profiling, allowing for better characterization of CNS diseases. The launch aims to expand the patient population served and enhance the information available to physicians managing CNS cancers.

Read more →
-CNSY
Sep 30, 2026
CNSYGeneral

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Cerenome, Inc. reported a positive business update for CNSide Diagnostics, highlighting $1.55 million in gross billings for Q3 2026. The company is on track to expand its testing menu and expects to cover approximately 200 million lives by early 2027. A favorable CMS pricing decision for its TCE Test is anticipated to take effect in January 2027.

Read more →
-CNSY
Sep 25, 2026
CNSYConferences/Events
▲ +6.4%on this newsshared move

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

Cerenome, Inc. announced a business update call for its CNSide Diagnostics platform on September 30, 2026. The call will cover recent commercial developments, including billing and market access improvements. CEO Marc H. Hedrick highlighted the progress made since the platform's launch in early 2026 and aims to inform stakeholders about future growth plans.

Read more →
-CNSY
Sep 22, 2026
CNSYGeneral
▲ +6.8%on this newsshared move

Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives

Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Blue Cross Blue Shield of Michigan, enhancing coverage for its CNSide® CSF Tumor Cell Enumeration assay. This agreement, effective September 1, 2026, brings the total covered lives to approximately 158 million. The move is part of Cerenome's strategy to improve patient access and support physician adoption of its diagnostic tests.

Read more →
-CNSY
Sep 16, 2026
CNSYGeneral

Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division

Cerenome, Inc. has appointed Samantha Fowlkes as Vice President and Head of Commercial Sales for CNSide Diagnostics. With over two decades of experience in oncology diagnostics, Fowlkes will lead the commercial expansion of the CNSide platform. Her appointment is seen as crucial for enhancing relationships within the oncology community and accelerating the adoption of CNSide's innovative diagnostic technologies.

Read more →
-CNSY
Sep 10, 2026
CNSYGeneral

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Cerenome, Inc. has announced a financing agreement with 3i, LP for up to $20 million, aimed at supporting the scale-up of its CNSide® cerebrospinal fluid assay platform. The initial funding has been received, with future tranches contingent on achieving specific milestones. This financing is expected to extend the company's cash runway into 2028.

Read more →
-CNSY
Aug 20, 2026
CNSYConferences/Events
▼ -6%on this news

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Cerenome presented key findings at the 2026 SNO/ASCO CNS Metastases Conference, highlighting the pharmacokinetics and safety of REYOBIQ in treating leptomeningeal metastases. The ongoing trials show promising safety signals and effective drug activity. Additionally, a cost-of-care analysis indicates that earlier detection and management could significantly reduce treatment costs for patients.

Read more →
-CNSY
Aug 14, 2026
CNSYGeneral
▼ -13%on this newsshared move

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Cerenome, Inc. reported its second quarter 2026 financial results, highlighting substantial progress in its CNS oncology platform and a successful rebranding from Plus Therapeutics. The company continues to enroll patients in multiple clinical trials for its lead therapeutic REYOBIQ, with no dose-limiting toxicities reported. However, the company experienced a significant increase in operating loss compared to the previous year.

Read more →
-CNSY
Aug 13, 2026
CNSYGeneral

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

Cerenome signed an in-network agreement with Health Care Service Corporation for its CNSide assay. This deal adds 27.3 million covered lives to the company’s network. Total contracted coverage now exceeds 150 million lives. This result meets the firm’s full-year 2026 commercial payer coverage objective ahead of schedule.

Read more →
-CNSY
Aug 6, 2026
CNSYGeneral

Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform

Cerenome selected XiFin to manage billing for its CNSide platform. The company will start billing in the third quarter of 2026. This move addresses an accumulated backlog of tests from the previous period. The automated system aims to support higher volumes without increasing administrative costs.

Read more →
-CNSY
Jul 31, 2026
CNSYGeneral

Cerenome Launches as an Integrated CNS Oncology Company

Cerenome, formerly Plus Therapeutics, has launched as an integrated company focusing on CNS oncology. The company aims to enhance the detection, treatment, and understanding of CNS cancers through precision diagnostics, targeted therapeutics, and artificial intelligence. This strategic rebranding signifies a commitment to innovation in the oncology field.

Read more →

About Cerenome, Inc.

Houston, TX 28 employees cerenome.com
Headquarters6420 LEVIT GREEN BOULEVARD, HOUSTON, TX, 77021
BIOPHARMAWATCH ELITE
Trade the next CNSY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime